Kornimate/medical-research-clean huggingface dataset:
impact of different instrument modifications on lateral nasal wall osteotomy and pterygomaxillary separation in le fort i surgery

Conditions: Le Fort; I; Blood Loss

Summary: the aim of this study is to investigate the effect of different instrument modifications on the customized osteotomy of the lateral nasal wall in le fort i surgery, focusing on the level of lateral nasal wall fractures and the separation pattern of the pterygomaxillary junction. the primary hypothesis is blade osteotome is useful and facilitate the fracture line in ideal level both for lateral nasal wall and the pterygomaxillary junction.

while there are numerous studies in the literature evaluating various parameters related to maxillary down-fracture in le fort i osteotomy, studies specifically focused on lateral nasal osteotomy are very rare. there is no study in the literature has addressed customized lateral nasal osteotomy using different instruments. in our study, the lateral nasal wall osteotomy will be performed 2 mm shorter than the measured descending palatine ater distance in the axial computer tomography plane. one group (n=23) will use the routinely employed nievert osteotome (single guided osteotome), while the other group (n=23) will use a blade osteotome (no guided tip). this study aims to evaluate parameters such as the fracture pattern of the lateral nasal walls and the separation pattern of the pterygomaxillary junction by using different instrument modifications for lateral nasal wall osteotomy.

Eligibility criteria:
inclusion criteria: * patients requiring le fort i or bimaxillary surgery * patients who have not previously undergone le fort i or bimaxillary surgery (revision) * patients without cleft lip or palate * patients with no history of midface fractures or craniofacial trauma exclusion criteria: * patients with cleft lip and/or palate requiring orthognathic surgery * patients with a history of trauma needing orthognathic surgery for malocclusion correction * patients who have previously undergone orthognathic surgery and require revision surgery

Keywords: orthognthic surgery le fort i lateral nasal wall pterygomaxillary junction
letrozole pretreatment with misoprostol induction of abortion in first-trimester missed miscarriage

Conditions: Missed Abortion

Summary: this study compares the success rate of letrozole and misoprostol versus misoprostol alone for medical termination of first-trimester pregnancy among women with one or more previous cesarean deliveries.


Eligibility criteria:
inclusion criteria: * gestational age less than 64 days gestation (\<9 wks). * hemoglobin \>10 g/dl. * bmi between 18.5 kg/m2 and 25 kg/m2. * missed abortion. * previous one or more cesarean delivaries exclusion criteria: * molar pregnancy. * fibroid uterus. * uterine anomalies. * coagulopathy. * medical disorder that contraindicate induction of abortion (e.g. heart failure). * previous attempts for induction of abortion in the current pregnancy. * allergy to misoprostol or letrozole.
proton radiotherapy for pediatric brain tumors requiring partial brain irradiation

Conditions: Brain Tumor; Low Grade Glioma; Astrocytoma; Ependymoma; Ganglioglioma

Summary: some patients with brain tumors receive standard radiation to help prevent tumor growth. although standard radiation kills tumor cells, it can also damage normal tissue in the process and lead to more side effects. this research study is looking at a different form of radiation called proton radiotherapy which helps spare normal tissues while delivering radiation to the tumor or tumor bed. proton techniques irradiate 2-3 times less normal tissue then standard radiation. this therapy has been used in treatment of other cancers and information from those other research studies suggests that this therapy may help better target brain tumors then standard radiation.

- participants will receive proton radiotherapy at the francis h. burr proton therapy center which is located at the massachusetts general hospital. they will receive the proton radiotherapy 5 days per week. the number of weeks the participant will be receiving proton radiotherapy depends upon the tumor type and location and how well they are tolerating the treatment. participant's will have a physical exam weekly during proton radiotherapy treatment.

Eligibility criteria:
inclusion criteria: * biopsy proven low grade glioma or astrocytoma, ependymoma, craniopharyngioma, meningioma, neurocytoma, medulloblastoma or gangliogliomas or other rare tumor requiring tumor bed or tumor irradiation. patients with a presumed diagnosis of optic glioma or gliomas based on imaging and clinical characteristics will also be allowed on this trial. * patients with biopsy proven high grade glioma (excluding gbm) and a gross total resection and patients with non-disseminated atypical teratoid rhabdoid (atrt) may also be included. * pathologic diagnosis must be based on pathology or pathology review by department of pathology at mgh or another df/hcc institution. * age between 1-25 years. * life expectancy of greater than 1 year. * ecog performance status 0, 1, 2 or 3 or lansky performance status 30 or greater. * girls and women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. exclusion criteria: * participants who have had radiotherapy to the site to be treated. * participants with known spinal or distant metastases. patients with ependymoma, medulloblastoma or germinoma must have metastatic workup including spine mri to rule out metastases. * uncontrolled intercurrent illness that would limit compliance with study requirements. * pregnant or breastfeeding women. * patients who cannot participate in contributing to the neurocognitive outcomes due to severe neurologic impairment or language barrier (ie not english or spanish speaking) will be excluded from this study.

Keywords: proton radiotherapy
platelet-rich fibrin dressing in the management of free gingival graft

Conditions: Gingival Recession

Summary: evaluation of two dressing materials; a platelet-rich fibrin (prf) dressing and a non-eugenol-based (coe-pak™) dressing in the management of free gingival graft and donor site palatal wound.

evaluation of the usage of platelet-rich fibrin dressing in the management of free gingival graft and donor site palatal wound by evaluation of pain score, healing tissue in both donor and receiving sites, coverage of gingival recession, and the gain of attached gingiva. a total of 20 subjects will be invited to participate in this study from the patients seeking treatment at the department of periodontology, faculty of dentistry, damascus university. the study has been approved by the investigator's local review board. subjects will be recruited according to specific inclusion criteria. after completion of medical and dental history questionnaires, patients will sign a consent form after being advised about the nature of the study. patients will be allocated into two groups (10 patients each). a platelet-rich fibrin (prf) dressing will be used in both donor and receiving sites in the test group, while a non-eugenol-based (coe-pak™) dressing will be used in both donor and receiving sites in the control group . donor site working time, bleeding (ble), colour match (cm), pain and re-epithelization (ep) will be evaluated.

Eligibility criteria:
inclusion criteria: * patients of syrian descent. * systemically healthy. * attached gingival width ≤ 2 mm. * presence of type ii (miller classification) of gingival recession. exclusion criteria: * smoking. * pregnancy or lactating. * presence of any systematic diseases can affect the periodontal surgery. * subjects with significant moderate to severe periodontal disease. * patients under orthodontic treatment * presence of restorative materials (e.g. crown) * subjects have failed to maintain good plaque control. * subjects having previous surgical treatment for covering the recession in the chosen area.

Keywords: autografts gingival recession free gingival graft attached gingival width platelet-rich fibrin dressing
"prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients"

Conditions: Breast Cancer Female; Peripheral Neuropathy

Summary: the aim of this study is to evaluate the effect of pentoxifylline 400 mg twice daily administration on the prevention of paclitaxel-induced peripheral neuropathy in breast cancer patients.

paclitaxel induced peripheral neuropathy (pipn) starts early during therapy and may worsen even after cessation and affect mainly sensory neurons. the symptoms of neuropathy include pain, tingling, cold-sensitivity and numbness that typically presents in a stocking glove distribution. the pathogenesis of pipn may be attributed to drug accumulation in dorsal root ganglia causing increase in inflammatory cytokines, immune mediators and dysregulation of calcium subunits which in turn increases pain. it also causes oxidative stress in sensory axons leading to axon demyelination, increased sensitization to signal transduction, release of pro-inflammatory mediators and activation of apoptosis. many animal studies and clinical trials have shown pentoxifylline to have a significant anti-inflammatory and antioxidant effect. it also preserved nerve conduction velocity and ameliorated mechanical hyperalgesia. pentoxifylline showed a prominent reduction in neuropathic pain in diabetic patients. these effects were mainly due to the ability of pentoxifylline to reduce tnf-α and mda levels. so, pentoxifylline is a drug of interest due to its ability to ameliorate neuro-inflammation and oxidative stress which play a critical role in pipn pathogenesis.

Eligibility criteria:
inclusion criteria: * adult patients (18-80 years old). * female patients. * pathologically proved breast cancer. * breast cancer patients who will receive adjuvant and neoadjuvant weekly paclitaxel for 12 weeks. * eastern cooperative oncology group (ecog) performance ≤ 2 * adequate bone marrow function. * adequate liver and kidney function. exclusion criteria: * patients with preexisting clinical neuropathy. * patients with diabetes mellitus. * metastatic breast cancer. * patients receiving medications that ameliorate neuropathy like; antidepressants, anticonvulsants, opioids, adjuvant or topical analgesics. * patients treated with medications that increase the risk of neuropathy. * hypersensitivity to pentoxifylline or xanthine derivatives. * patients with recent (within 1 month) surgery, myocardial infarction (mi), intracranial or retinal bleeding or active peptic ulcer. * patients at high risk for bleeding or taking medications that increase risk of bleeding.

Keywords: breast cancer pentoxifylline paclitaxel taxol peripheral neuropathy trental
ganoderma tea on eczema patient

Conditions: Eczema

Summary: this is a single-blind, cross-over pilot study to observe the safety and efficacy of ganoderma tea on eczema patients.

objective this study is to conduct a preliminary observation on the effect of a master ganoderma detox tea in improving eczema symptoms. because it is a preliminary study, there will not be a placebo control. however, in order to exclude the impact of spontaneous improvement, we will set up a cross over control group. thus, we want to find out whether there is any difference in taking the tea and without taking the tea. research design this is a randomized, cross-over-control and assessor-blinded clinical trial. subjects will be divided into groups a and group b. group a will receive the intervention for 8 weeks, followed by an 8-week period of no intervention. group b will be observed without having any intervention for 8 weeks, and then receive the intervention for 8 weeks. randomization will be carried out using a computer program. interventions subjects in the treatment group (a) will take the a master ganoderma detox tea for 8 weeks. initially, the dosage is twice a day, one pack (5g) each time, and then increased to three times a day, two packs each time within two weeks. the control group (b) will not receive any study intervention for 8 weeks, followed by similar intervention for 8 weeks. in case of allergies or severe adverse reactions occur, the subject should stop taking the tea immediately and be excluded from the trial. during the control or intervention period, if necessary, subject may use short-term steroids or other topical medication to relieve the symptoms of eczema.

Eligibility criteria:
inclusion criteria: * eczema for 1 year, without other systemic illness. exclusion criteria: * severe systemic illness, * oral steroid in the last month
low power laser and exercise in osteoarthritis of the knee: a randomized clinical trial

Conditions: Osteoarthritis

Summary: indroduction: knee osteoarthritis (oa) is a painful condition causing disability, weakness and poor quality of live. the results are very consistent about the benefits of laser and exercises to improve pain and function in subjects with knee osteoarthritis objectives: to investigate the effects of low power laser (lbp) associated with exercise in pain, function, range of motion, muscle strength and quality of life of patients with knee osteoarthritis. methods: forty patients of both sexes aged between 50 and 75 years with knee osteoarthritis (grade 2-4) were randomized into two groups: laser-lbp-active dose of 3j more exercises and group placebo-lbp- placebo and exercise. were evaluated for pain, function, range of motion, muscle strength and quality of life on three occasions: before starting treatment (evaluation 1), 3 weeks after laser application (evaluation 2) and 8 weeks after completion of exercise (evaluation 3). there were 33 physical therapy sessions three times a week, on march 1 and the laser was applied in the other, only the exercises.

pain: pain intensity was measured with the visual analogue scale (vas) which is a straight 10 cm long devoid of numbers, in which there is only an indication of the extreme left of "no pain" and extreme right to "unbearable pain". the higher the score, the greater the pain. feature: survey conducted by lequesne, which is an index composed of 11 questions about pain, discomfort and function. the scores range from 0 to 24 (without affecting the extremely severe, respectively), the higher the score, the greater the impairment. range of motion (rom): adm flexion and knee extension was measured using a universal goniometer (aesculap) with the patient prone second methodology marques. muscular strength: to assess the maximal isometric strength of the quadriceps muscle was used dynamometer model lafayette ® portable (usa), while seated at 60 ° of knee flexion and this gradation was controlled with a goniometer. patients remained seated on the stretcher and held steady with thigh extension strength, the dynamometer being maintained in the distal leg. three measurements were taken, and the mean value. quality of life: the questionnaire was used western ontario and mcmaster universities osteoarthritis (womac)a self-assessment that evaluates pain, stiffness and physical activity. the higher the score, the greater the impact of oa on quality of life.

Eligibility criteria:
inclusion criteria: * diagnoses of osteoarthritis * knee pain * functional reduction in the last three months * grade 2-4 oa * fulfilled at least one of the classification criteria of the american college of rheumatology exclusion criteria: * cancer * diabetes mellitus * symptomatic hip oa * antidepressants * anti-inflammatory steroidal and nonsteroidal or tranquilizers in the last six months and throughout the treatment

Keywords: osteoarthritis low power laser therapy exercise knee
correlation between smartphone use and text neck posture in asymptomatic subjects

Conditions: Smartphone Addiction; Text Neck Posture

Summary: this study will be conducted to investigate the correlation between the number of hours of smartphone usage and severity of text neck posture, cervical rom, dnf endurance and resting head posture among asymptomatic 18 to 25 years old adults

smartphone use has increased significantly globally, with 79% of adults aged 18-44 carrying a smartphone constantly. this can cause excessive anterior curves in the neck vertebrae and increase the mechanical load on cervical spine joints. overuse syndrome, spinal damage, and other side effects can result. this study aims to investigate the correlation between time spent using smartphones and text neck posture and its association with head and neck posture, cervical rom, and dnf endurance among asymptomatic 18-25-year-olds.

Eligibility criteria:
inclusion criteria: 1. individuals who are willing to participate at the time of data collection. 2. individuals aged 18 - 25 years old. 3. individuals who use a smartphone to report the duration of weekly usage (at least one year of using a smartphone and minimum duration of smartphone use of ≥1 h per day exclusion criteria: 1. previous history of an accident or severe injury. 2. any neurological or cardiovascular problem. 3. spinal surgery or any disease that prevents the individual from adopting an unsupported orthostatic posture. 4. congenital cervical problem. 5. pregnant women.

Keywords: forward head posture smart phone use
a study for patients who completed vitality-als (cy 4031)

Conditions: Amyotrophic Lateral Sclerosis (ALS)

Summary: the purpose of this study is to assess the long-term safety and tolerability of tirasemtiv in patients with als who had completed the double-blind placebo-controlled study of tirasemtiv in als (cy 4031).

enrolled participants will begin dosing of tirasemtiv 125 mg twice daily (250 mg/day) for a period of 4 weeks and will titrate to their tolerated dose, the maximum dose being 250 mg twice daily (500 mg/day). this study will also compare the clinical course of patients who completed treatment with tirasemtiv in cy 4031 with those who completed treatment with placebo in cy 4031 during continued treatment of both groups with tirasemtiv during cy 4033, compare the clinical course of patients who completed treatment with tirasemtiv in cy 4031 during that study with their clinical course during continued treatment with tirasemtiv during cy 4033, and compare the clinical course of patients who completed treatment with placebo in cy 4031 during that study with their clinical course during treatment with tirasemtiv during cy 4033.

Eligibility criteria:
inclusion criteria: * able to comprehend and willing to sign an informed consent form (icf). if verbal consent is given, a legal designee of the patient must sign the icf form * completed participation on study drug and the follow-up visit in the cy 4031 study * male patients, who have not had a vasectomy and confirmed zero sperm count, must agree for the duration of their participation in the study to either: * use a condom during sexual intercourse with female partners who are of childbearing potential and to have female partners use a highly effective means of contraception or * abstain from sexual intercourse during participation in the study * female patients who are not post-menopausal (≥ 1 year) or sterilized, must: * not be breastfeeding * have a negative pregnancy test * have no intention to become pregnant during participation in the study and * practice sexual abstinence, defined as refraining from intercourse during the duration of the study or if male partners are not vasectomized with a confirmed zero sperm count, require use of a condom and use of a highly effective contraceptive measure exclusion criteria: * has a diaphragm pacing system (dps) at study entry or anticipate dps placement during the course of the study * has taken an investigational study drug (other than tirasemtiv) prior to dosing, within 30 days or five half-lives of the prior agent, whichever is greater * use of tizanidine and theophylline-containing medications during study participation * participation or planning to participate in any form of stem cell therapy for the treatment of als or another investigational drug

Keywords: amyotrophic lateral sclerosis als tirasemtiv
study of different types of backache in groups of patients with different diagnoses of degenerative diseases

Conditions: Ache

Summary: the purpose of this study is to examine whether there are relations between different types of pain in groups of patients with different diagnoses of degenerative diseases of the spinal column and their related surgeries.

in the context of this work the pain of different groups of patients should be examined by means of the paindetect questionnaire, the roland-morris disability questionnaire, clinical examinations and different imaging procedures. two groups of patients are compared with each other. group one consists of patients with osteoporotic fractures of the vertebra. group two is formed by patients with osteochondria , spinal disc herniation and nerval compression. both groups of patients undergo surgery, as they are suffering from pain (e.g. kyphoplasty, nucleotomy, spondylodesis, decompression). in order to differentiate between chronic nociceptive pain and chronic neuropathic pain in these two groups the paindetect questionnaire is used. to examine the severity of disability in the patients' everyday life the roland-morris disability questionnaire is used. the included patients are examined and seen preoperative, postoperative before discharge from hospital, 6 weeks and 6 months after surgery.

Eligibility criteria:
inclusion criteria: * backache because of degenerative diseases * surgery is necessary exclusion criteria: -
temozolomide in relapsed or advanced anaplastic oligodendroglioma and oligoastrocytoma: single-arm, phase ii trial

Conditions: Anaplastic Oligodendroglioma; Anaplastic Oligoastrocytoma

Summary: the purpose of this study is to determine the efficacy and safety of temozolomide in patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma.

patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma will be enrolled. enrolled patients will begin on temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle). patients who were previously treated with any chemotherapy initially received temozolomide 150 mg/m2/d for 5 days (750 mg/m2 per cycle).patients will be receving a total 6 cycles of chemotheray (4weeks/cycle \* 6cycles = 24weeks). if the patients shows responses to temozolomide, treatment can be continued by the investigator's discretion. during the administration of temozolomide, vital signs, physical examination, ecog performance status, height, weight, hematology and chemistry test, adverse events and concomitant drugs will be evaluated every four weeks. brain mri for tumor assessment will be performed once every 12 weeks.

Eligibility criteria:
inclusion criteria: * histologically proven anaplastic oligodendroglioma or oligoastrocytoma * progressed or relapsed after surgery or radiation therapy * female or male aged 20 years or over * at least 1 measurable mass lesion * ecog performance status 0-3 * adequate organ function * absolute neutrophil count \> 1,500/μl * platelet count \> 75,000/μl * hemoglobin greater than 9 g/dl or 900g/l * serum creatinine less than 1.5 times the upper limit of laboratory normal * total serum bilirubin less than 1.5 times the upper limit of laboratory normal * ast or alt less than three times the upper limit of laboratory normal exclusion criteria: * prior course of temozolomide * combined glioblastoma * pregnant woman

Keywords: temozolomide